<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="abs0010">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="lis0045">
   <list-item id="lsti0070">
    <label>•</label>
    <p id="par0070">Lysosomotropic drugs show moderate antiviral effects even on coronaviruses.</p>
   </list-item>
   <list-item id="lsti0075">
    <label>•</label>
    <p id="par0075">The antiviral activity is likely due to interference with endosomal pathway.</p>
   </list-item>
   <list-item id="lsti0080">
    <label>•</label>
    <p id="par0080">530 existing drugs were analysed for lysosomotropism, pharmacokinetics and toxicity.</p>
   </list-item>
   <list-item id="lsti0085">
    <label>•</label>
    <p id="par0085">36 drugs were identified that may possibly be suitable for repurposing for COVID-19.</p>
   </list-item>
   <list-item id="lsti0090">
    <label>•</label>
    <p id="par0090">Further research is needed to confirm their antiviral effects and safety limits.</p>
   </list-item>
  </list>
 </p>
</abstract>
